Researcher Profile

Geraldine Helen O'Sullivan Coyne

🏛 Developmental Therapeutics Clinic/Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD;

Publications

Citations

Co-Authors

Active Years

Publications

Journal Article Journal of Clinical Oncology May 20, 2020

Phase II trial of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886 Hydrogen Sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).

Geraldine Helen O'Sullivan Coyne · Andrea M. Gross · Eva Dombi · Cecilia Tibery +14 more

10.1200/jco.2020.38.15_suppl.3612 23 citations

Publication Timeline

2020

Frequent Co-Authors

1×

1×

1×

1×

1×

1×

1×

1×

1×

1×